Hemogenyx Pharmaceuticals (LON:HEMO) Posts Earnings Results

Key Points

• Hemogenyx Pharmaceuticals reported earnings of GBX (0.83) per share for the quarter, indicating continued financial activity amidst its developmental focus.
• The company's stock remained flat at GBX 1,162.50 during trading, with a market capitalization of £54.95 million.
• Hemogenyx is concentrating on therapies for blood diseases, including developments for acute myeloid leukaemia and bone marrow transplant treatments.

Hemogenyx Pharmaceuticals (LON:HEMO - ) issued its quarterly earnings data on Tuesday. The company reported GBX (0.83) earnings per share for the quarter, Digital Look Earnings reports.

Hemogenyx Pharmaceuticals Stock Performance

LON HEMO remained flat at GBX 1,162.50 during trading on Tuesday. 76,521 shares of the company's stock traded hands, compared to its average volume of 65,417. The company has a current ratio of 4.38, a quick ratio of 6.72 and a debt-to-equity ratio of 90.87. Hemogenyx Pharmaceuticals has a 1-year low of GBX 124 and a 1-year high of GBX 1,800. The firm has a market capitalization of £54.95 million, a P/E ratio of -641.91 and a beta of 3.14. The stock has a 50 day simple moving average of GBX 561.54 and a two-hundred day simple moving average of GBX 308.52.

About Hemogenyx Pharmaceuticals

Hemogenyx Pharmaceuticals Plc, a preclinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies and treatments for blood diseases. It is involved in developing products for bone marrow/hematopoietic stem cell (BM/HSC) transplant market, including CDX bi-specific antibody targeting relapsed/refractory acute myeloid leukaemia (R/R AML); HEMO-CAR-T therapy, a chimeric antigen receptor T-cells to identify and destroy human AML-derived cells in vitro and in vivo; and Human Postnatal Hematopoietic Endothelial Cells, a stem cell therapy product for BM/HSC transplants.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.